Alphabet’s healthcare subsidiary, Verily, will partner with Swiss Re Corporate Solutions to create a new stop-loss insurance company. The new entity, called Coefficient, will use data analytics to help self-funded companies manage unexpected areas of cost.
Verily, Alphabet’s life sciences arm, is launching a new study to better understand the immune response to Covid-19 and gain more information on the accuracy of tests.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
After declaring a state of emergency on Friday, Trump announced that Google would be building a website that could route users to drive-thru testing sites for COVID-19. Alphabet’s subsidiary, Verily, said the tool was in the early stages of development, and that it planned to roll out testing in the Bay Area.
The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.
The partnership adds to Verily’s growing work in value-based reimbursement.
Color vice president for research and scientific affairs Alicia Zhou explained that there is an ethical obligation to provide information on actionable genes, but costs and logistics have previously made doing so prohibitive.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Verily is being paid by iRhythm Technologies to develop a tool by improving existing hardware and software to effectively diagnose patients with asymptomatic atrial fibrillation.
The regulator is opening up the program to 510(k) submissions, instead of its initial focus on companies moving through the De Novo regulatory pathway.
The company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.
The organizations have announced that the first real-world clinical use of the algorithm is happening at the Aravind Eye Hospital in Madurai, India.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Redwood City, California-based Auris Health may also receive up to $2.35 billion in additional payments dependent on hitting certain predetermined milestones.
While the Study Watch was designed as investigational tool, it's likely the company will integrate features developed on the device onto its more consumer-oriented offerings.
At the CES Digital Health Summit, Daniel Kraft and leaders from Fitbit Health Solutions, Verily and Akili Interactive explored how far we've come and where we're going when it comes to digital health.
San Diego-based Dexcom said at the annual J.P. Morgan Healthcare Conference in San Francisco that it's first-gen product co-developed by Alphabet's Verily may never get launched in the U.S.
Alphabet CFO Ruth Porat and Silver Lake Managing Director Egon Durban will be nominated to join Verily's operating board.